IP-001 is named as an intervention in 2 current clinical trials in our UK, USA, Germany, France, Switzerland and Netherlands registers. 1 is recruiting patients now. All registered phases are Phase 1/2. The sponsor with the most trials is Immunophotonics, Inc (1). The most-studied condition is Metastatic Solid Tumor.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM
NCT06630624 · ClinicalTrials.gov ↗ · Colorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer
|
Phase 1/2 | Recruiting | M.R. Meijerink | Netherlands |
|
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
NCT05688280 · ClinicalTrials.gov ↗ · Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer
|
Phase 1/2 | Active, closed | Immunophotonics, Inc | UK, USA, Germany, France, Switzerland |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Immunophotonics, Inc | 1 |
| M.R. Meijerink | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in UK | 1 | 0 |
| Clinical trials in USA | 1 | 0 |
| Clinical trials in Germany | 1 | 0 |
| Clinical trials in France | 1 | 0 |
| Clinical trials in Switzerland | 1 | 0 |
| Clinical trials in Netherlands | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our UK, USA, Germany, France, Switzerland and Netherlands registers name IP-001 as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in Netherlands. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Immunophotonics, Inc (1) and M.R. Meijerink (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how IP-001 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how IP-001 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists IP-001 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.